Beloranib
An Efficacy, Safety and Pharmacokinetics Study of Beloranib (ZGN-440 for Injectable Suspension) in Obese Subjects
Zafgen · Phase 2 · Completed · Enrollment 160
| Arm | Nausea | Vomiting | Diarrhea | Discontinuation | Deaths |
|---|---|---|---|---|---|
| Placebo | n/r | n/r | n/r | n/r | n/r |
| 0.3 mg Beloranib | n/r | n/r | n/r | n/r | n/r |
| 0.6 mg Beloranib | n/r | n/r | n/r | n/r | n/r |
| 1.2 mg Beloranib | n/r | n/r | n/r | n/r | n/r |
| 2.4 mg Beloranib | n/r | n/r | n/r | n/r | n/r |
| 3.2 mg Beloranib | n/r | n/r | n/r | n/r | n/r |
A count stays a count. This page does not turn a count into a percent.